New antibody drug aims to ease double vision and bulging eyes in thyroid disease
NCT ID NCT07152392
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a drug called IBI311 in 50 people with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. IBI311 is an antibody that blocks a protein involved in the disease. The goal is to see if it improves eye symptoms and is safe. Participants will receive the drug and be followed for six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI311 (a lab-made antibody that blocks a protein called IGF-1R, given as an injection)
- What this could lead to
- If it works, this could offer a new treatment option for people with inactive thyroid eye disease to reduce double vision and eye bulging.
- What could go wrong
- This is a small, early-phase study with only 50 participants, so results may not apply to everyone. The drug may cause side effects or not improve symptoms significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, Shanghai Municipality, 200003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI reads eye scans to spot thyroid disease activity and severity
- Could your Phone's camera help track thyroid eye disease?
- Can eye tracking reveal hidden effects of thyroid eye disease?
- New antibody injection could ease bulging eyes in thyroid disease
- New combo therapy aims to tame thyroid eye disease
- New antibody IBI311 takes on steroids in Head-to-Head trial for thyroid eye disease